About this Research Topic
“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.
This Research Topic aims to highlight the work featured and spark further discussion. The Cancer Genetics field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.
We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.
The chosen manuscripts are :
- FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
- Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas
- The Detection of Cancer Epigenetic Traces in Cell-Free DNA
- Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma
- Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
- Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer
- LncRNA-Encoded Peptide: Functions and Predicting Methods
- The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
This Research Topic aims to highlight the work featured and spark further discussion. The Cancer Genetics field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.
We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.
The chosen manuscripts are :
- FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
- Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas
- The Detection of Cancer Epigenetic Traces in Cell-Free DNA
- Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma
- Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
- Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer
- LncRNA-Encoded Peptide: Functions and Predicting Methods
- The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: genetics, cancer, oncogenomics, biomarker
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
